周力力,张毅,王捷

• 1:上海市第十人民医院心内科
• 2:同济大学医学院
• 3:江苏省人民医院

摘要(Abstract)：

高血压作为最常见的心血管疾病，存在患病率高、知晓率低、控制率低的问题。由于药物治疗的局限性，近十年来，经皮去肾神经术（RDN）作为一种新兴的治疗高血压介入手段脱颖而出。经过长达十余年的循证医学研究证明了该技术在降压方面的有效性与安全性。目前，RDN临床试验的挑战在于患者为了控制血压而无法避免对降压药物进行调整，从而对RDN降压效果产生干扰。无论是Simplicity HTN-3 6个月试验和REQUIRE试验等失败案例，还是SPYRAL与RADIANCE系列试验，其结果都表明RDN临床试验的结果评估需要纳入降压药物的变化。因为降压药物与介入手术治疗是影响血压水平的两个决定因素，所以评估RDN的降压疗效时不得不考虑患者降压药物的调整，还要回答一个重大临床问题即RDN术后患者是否可以少服以至不服用药物。我国的SMART研究不再以单纯的血压可以降低的mm Hg数，而是以高血压防治指南中的治疗目标即诊室血压达标率为主要终点之一；引入了预设的“药物负荷指数”并将诊室收缩压（OSBP）达标率和降压用药变化作为临床试验的复合终点。其结果证明了RDN作为降压的辅助疗法，可以显著降低患者的药物负荷水平，将患者的OSBP控制达标。在未来的RDN临床试验中，应当充分考虑药物负荷的影响，明确血压指标和受试人群。RDN治疗高血压的临床试验方式会更加多元化，包括更能回答临床重大问题和符合治疗指南的有效性终点、更多种消融能量平台的尝试、术中手术终点的判定和试验对照组的设定等。

关键词(KeyWords)： 高血压;经皮去肾神经术;药物负荷;临床研究;血压

Abstract:

Keywords:

基金项目(Foundation): 国家自然基金面上项目（82370300）

作者(Author): 周力力,张毅,王捷

参考文献(References)：

• [1] GBD 2019 Risk Factors Collaborators.Global burden of 87risk factors in 204 countries and territories, 1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet,2020,396(10258):1223-1249. DOI:10.1016/S0140-6736(20)30752-2.
• [2] NCD Risk Factor Collaboration(NCD-RisC).Worldwide trends in hypertension prevalence and progress in treatment and control from1990 to 2019:a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet,2021,398(10304):957-980. DOI:10.1016/S0140-6736(21)01330-1.
• [3]马丽媛，王增武，樊静，等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志，2022,30(7):481-496. DOI:10. 3969/j. issn. 1004-8812. 2022. 07. 001.
• [4] Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among us adults with hypertension, 1999-2000 to 2017-2018[J]. JAMA,2020,324(12):1190-1200. DOI:10.1001/jama.2020.14545.
• [5] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension[J]. Eur Heart J,2018,39(33):3021-3104. DOI:10.1093/eurheartj/ehy339.
• [6] Townsend RR, Mahfoud F, Kandzari DE, et al. Catheterbased renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTNOFF MED):a randomised, sham-controlled, proof-ofconcept trial[J]. Lancet,2017,390(10108):2160-2170.DOI:10.1016/S0140-6736(17)32281-X.
• [7] Kandzari DE, B?hm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTNON MED proof-of-concept randomised trial[J]. Lancet, 2018,391(10137):2346-2355. DOI:10.1016/S0140-6736(18)30951-6.
• [8] B?hm M, Kario K, Kandzari DE, et al. Efficacy of catheterbased renal denervation in the absence of antihypertensive medications(SPYRAL HTN-OFF MED Pivotal):a multicentre,randomised, sham-controlled trial[J]. Lancet, 2020,395(10234):1444-1451. DOI:10.1016/S0140-6736(20)30554-7.
• [9] Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension(RADIANCE-HTN SOLO):a multicentre, international, single-blind, randomised, shamcontrolled trial[J]. Lancet,2018,391(10137):2335-2345.DOI:10.1016/S0140-6736(18)31082-1.
• [10] Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill(RADIANCEHTN TRIO):a randomised, multicentre, single-blind, shamcontrolled trial[J]. Lancet,2021,397(10293):2476-2486.DOI:10.1016/S0140-6736(21)00788-1.
• [11] Townsend RR, Ferdinand KC, Kandzari DE, et al. Impact of antihypertensive medication changes after renal denervation among different patient groups:SPYRAL HTN-ON MED[J].Hypertension,2024,81(5):1095-1105. DOI:10.1161/HYPERTENSIONAHA.123.22251.
• [12] Mancia G, Kreutz R, Brunstr?m M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension:endorsed by the International Society of Hypertension(ISH)and the European Renal Association(ERA)[J]. J Hypertens,2023,41(12):1874-2071.DOI:10.1097/HJH.0000000000003480.
• [13] Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by highperformance liquid chromatography-tandem mass spectrometry(HP LC-MS/MS)urine analysis[J]. Heart,2014,100(11):855-861. DOI:10.1136/heartjnl-2013-305063.
• [14] Bakris GL, Townsend RR, Liu M, et al. Impact of renal denervation on 24-hour ambulatory blood pressure:results from Symplicity HTN-3[J]. J Am Coll Cardiol, 2014,64(11):1071-1078. DOI:10.1016/j.jacc.2014.05.012.
• [15] Kario K, Yokoi Y, Okamura K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension:the randomized, controlled REQUIRE trial[J]. Hypertens Res,2022,45(2):221-231. DOI:10.1038/s41440-021-00754-7.
• [16] Azizi M, Sharp ASP, Fisher NDL, et al. Patient-level pooled analysis of endovascular ultrasound renal denervation or a sham procedure 6 months after medication escalation:the RADIANCE clinical trial program[J]. Circulation,2024,149(10):747-759. DOI:10.1161/CIRCULATIONAHA.123.066941.
• [17] Kandzari DE, Hickey GL, Pocock SJ, et al. Prioritised endpoints for device-based hypertension trials:the win ratio methodology[J]. EuroIntervention,2021,16(18):e1496-e1502. DOI:10.4244/EIJ-D-20-01090.
• [18] Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs(SPYRAL HTN-ON MED):a randomised, shamcontrolled trial[J]. Lancet,2022,399(10333):1401-1410. DOI:10.1016/S0140-6736(22)00455-X.
• [19] Wang Y, Wang JW, Wang Y, et al. Monitoring antihypertensive medication adherence by liquid chromatographytandem mass spectrometry:method establishment and clinical application[J]. J Cardiovasc Pharmacol,2021,78(4):581-596. DOI:10.1097/FJC.0000000000001105.
• [20] Wang J, Yin Y, Lu C, et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension(SMART):6-month follow-up of a randomised, controlled trial[J]. EClinicalMedicine,2024,72:102626. DOI:10.1016/j.eclinm.2024.102626.
• [21]胡鑫渝，周浩，李丹，等.聚焦去肾交感神经术发展的关键——患者选择与精准消融[J].中国介入心脏病学杂志，2023,31(3):213-218. DOI:10.3969/j.issn.1004-8812.2023.03.008.
• [22]李悦，卢成志.经皮去肾神经术：最新证据与患者筛选[J].心血管病学进展，2024,45(3):211-215. DOI:10.16806/j.cnki.issn.1004-3934.2024.03.005.
• [23] Huang HC, Pan HY, Wang TD. Renal nerve stimulation predicted blood pressure-lowering responses to percutaneous renal denervation[J]. Circ Cardiovasc Interv,2023,16(2):e012779. DOI:10.1161/CIRCINTERVENTIONS.122.012779.
• [24]李月平，卢成志，蒋雄京，等.经皮去肾神经术治疗高血压中国专家科学声明[J].中国介入心脏病学杂志，2023,31(12):881-893. DOI:10.3969/j.issn.1004-8812.2023.12.001.